PRECISION BIOSCIENCES INC (DTIL) Stock Fundamental Analysis

NASDAQ:DTIL • US74019P2074

3.95 USD
+0.16 (+4.22%)
At close: Feb 23, 2026
3.81 USD
-0.14 (-3.54%)
After Hours: 2/23/2026, 5:23:50 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

DTIL gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. DTIL has a bad profitability rating. Also its financial health evaluation is rather negative. DTIL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • DTIL had negative earnings in the past year.
  • In the past year DTIL has reported a negative cash flow from operations.
  • In the past 5 years DTIL reported 4 times negative net income.
  • DTIL had a negative operating cash flow in each of the past 5 years.
DTIL Yearly Net Income VS EBIT VS OCF VS FCFDTIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • DTIL has a Return On Assets of -89.40%. This is in the lower half of the industry: DTIL underperforms 71.98% of its industry peers.
  • With a Return On Equity value of -502.60%, DTIL is not doing good in the industry: 75.24% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -89.4%
ROE -502.6%
ROIC N/A
ROA(3y)-26.66%
ROA(5y)-33.41%
ROE(3y)-165.71%
ROE(5y)-155.21%
ROIC(3y)N/A
ROIC(5y)N/A
DTIL Yearly ROA, ROE, ROICDTIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DTIL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DTIL Yearly Profit, Operating, Gross MarginsDTIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • DTIL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DTIL has been increased compared to 1 year ago.
  • The number of shares outstanding for DTIL has been increased compared to 5 years ago.
  • Compared to 1 year ago, DTIL has a worse debt to assets ratio.
DTIL Yearly Shares OutstandingDTIL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
DTIL Yearly Total Debt VS Total AssetsDTIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -10.21, we must say that DTIL is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of DTIL (-10.21) is worse than 72.36% of its industry peers.
  • A Debt/Equity ratio of 1.35 is on the high side and indicates that DTIL has dependencies on debt financing.
  • DTIL's Debt to Equity ratio of 1.35 is on the low side compared to the rest of the industry. DTIL is outperformed by 76.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Altman-Z -10.21
ROIC/WACCN/A
WACC8.66%
DTIL Yearly LT Debt VS Equity VS FCFDTIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • DTIL has a Current Ratio of 3.45. This indicates that DTIL is financially healthy and has no problem in meeting its short term obligations.
  • DTIL has a Current ratio (3.45) which is in line with its industry peers.
  • DTIL has a Quick Ratio of 3.45. This indicates that DTIL is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of DTIL (3.45) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
DTIL Yearly Current Assets VS Current LiabilitesDTIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • DTIL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -322.11%.
  • The Revenue for DTIL has decreased by -99.07% in the past year. This is quite bad
  • The Revenue has been growing by 25.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-322.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.22%
Revenue 1Y (TTM)-99.07%
Revenue growth 3Y-15.91%
Revenue growth 5Y25.3%
Sales Q2Q%-97.74%

3.2 Future

  • The Earnings Per Share is expected to decrease by -88.77% on average over the next years. This is quite bad
  • The Revenue is expected to decrease by -9.95% on average over the next years.
EPS Next Y-4071.8%
EPS Next 2Y-340.23%
EPS Next 3Y-166.95%
EPS Next 5Y-88.77%
Revenue Next Year-87.36%
Revenue Next 2Y-58.79%
Revenue Next 3Y-36.83%
Revenue Next 5Y-9.95%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DTIL Yearly Revenue VS EstimatesDTIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
DTIL Yearly EPS VS EstimatesDTIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • DTIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DTIL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DTIL Price Earnings VS Forward Price EarningsDTIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DTIL Per share dataDTIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

  • A cheap valuation may be justified as DTIL's earnings are expected to decrease with -166.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-340.23%
EPS Next 3Y-166.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DTIL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRECISION BIOSCIENCES INC

NASDAQ:DTIL (2/23/2026, 5:23:50 PM)

After market: 3.81 -0.14 (-3.54%)

3.95

+0.16 (+4.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)03-24
Inst Owners23.62%
Inst Owner Change191.46%
Ins Owners4.74%
Ins Owner Change1.32%
Market Cap90.45M
Revenue(TTM)698.00K
Net Income(TTM)-83.60M
Analysts86
Price Target33.15 (739.24%)
Short Float %6.49%
Short Ratio5.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-33.96%
Min EPS beat(2)-34.62%
Max EPS beat(2)-33.29%
EPS beat(4)0
Avg EPS beat(4)-26.25%
Min EPS beat(4)-34.62%
Max EPS beat(4)-10.86%
EPS beat(8)2
Avg EPS beat(8)34.02%
EPS beat(12)5
Avg EPS beat(12)30.59%
EPS beat(16)7
Avg EPS beat(16)24.06%
Revenue beat(2)0
Avg Revenue beat(2)-99.74%
Min Revenue beat(2)-99.76%
Max Revenue beat(2)-99.72%
Revenue beat(4)0
Avg Revenue beat(4)-96.07%
Min Revenue beat(4)-99.76%
Max Revenue beat(4)-85.37%
Revenue beat(8)2
Avg Revenue beat(8)14.83%
Revenue beat(12)6
Avg Revenue beat(12)39.13%
Revenue beat(16)7
Avg Revenue beat(16)24.26%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 129.59
P/FCF N/A
P/OCF N/A
P/B 5.44
P/tB 5.78
EV/EBITDA N/A
EPS(TTM)-8.4
EYN/A
EPS(NY)-2.91
Fwd EYN/A
FCF(TTM)-3.22
FCFYN/A
OCF(TTM)-3.2
OCFYN/A
SpS0.03
BVpS0.73
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -89.4%
ROE -502.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.66%
ROA(5y)-33.41%
ROE(3y)-165.71%
ROE(5y)-155.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.14%
Cap/Sales 61.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z -10.21
F-Score1
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)28.02%
Cap/Depr(5y)41.2%
Cap/Sales(3y)6.1%
Cap/Sales(5y)8.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-322.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.22%
EPS Next Y-4071.8%
EPS Next 2Y-340.23%
EPS Next 3Y-166.95%
EPS Next 5Y-88.77%
Revenue 1Y (TTM)-99.07%
Revenue growth 3Y-15.91%
Revenue growth 5Y25.3%
Sales Q2Q%-97.74%
Revenue Next Year-87.36%
Revenue Next 2Y-58.79%
Revenue Next 3Y-36.83%
Revenue Next 5Y-9.95%
EBIT growth 1Y-452.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-263.34%
EBIT Next 3Y-30.92%
EBIT Next 5Y-0.71%
FCF growth 1Y26.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.87%
OCF growth 3YN/A
OCF growth 5YN/A

PRECISION BIOSCIENCES INC / DTIL FAQ

Can you provide the ChartMill fundamental rating for PRECISION BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 1 / 10 to DTIL.


Can you provide the valuation status for PRECISION BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to PRECISION BIOSCIENCES INC (DTIL). This can be considered as Overvalued.


How profitable is PRECISION BIOSCIENCES INC (DTIL) stock?

PRECISION BIOSCIENCES INC (DTIL) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for DTIL stock?

The Earnings per Share (EPS) of PRECISION BIOSCIENCES INC (DTIL) is expected to decline by -4071.8% in the next year.


How sustainable is the dividend of PRECISION BIOSCIENCES INC (DTIL) stock?

The dividend rating of PRECISION BIOSCIENCES INC (DTIL) is 0 / 10 and the dividend payout ratio is 0%.